Larimar Therapeutics, Inc. 8-K

What Happened

• On January 12, 2026, Larimar Therapeutics, Inc. (LRMR) posted an updated corporate slide presentation and filed a Current Report on Form 8‑K (Item 2.02 and 8.01) disclosing a preliminary, unaudited cash, cash equivalents and marketable securities balance of approximately $136.9 million as of December 31, 2025. The presentation is attached to the filing as Exhibit 99.1 and will be used in investor and analyst meetings.
• The company stated it has not completed its quarter‑end or year‑end close procedures; the $136.9M figure was prepared by management, is unaudited, may change upon completion of closing procedures, and PricewaterhouseCoopers LLP has not audited or reviewed this preliminary data. Final results will be included in Larimar’s Form 10‑K for the year ended December 31, 2025.

Key Details

• Date filed: January 12, 2026.
• Preliminary cash, cash equivalents and marketable securities: approximately $136.9 million as of December 31, 2025.
• Amount is unaudited and prepared by management; subject to change upon completion of financial close.
• PricewaterhouseCoopers LLP has not performed any audit, review or compilation procedures on this preliminary figure.
• Updated corporate slide deck (Exhibit 99.1) posted on the company website and incorporated by reference in the 8‑K.

Why It Matters

• Liquidity snapshot: The disclosed $136.9M gives investors an interim view of Larimar’s available liquidity heading into 2026, which is a key input for assessing runway and funding needs.
• Preliminary nature: Because the amount is unaudited and subject to change, investors should wait for the company’s audited 2025 Form 10‑K for final financials; the 8‑K explicitly warns the final results may differ materially.
• Next steps for investors: Monitor the Form 10‑K filing for audited year‑end balances and any discussion of cash burn, revenue or financing plans that would put the preliminary cash figure in context.